On October 26, 2026, two biotech companies based in Massachusetts, Fractyl Health and EyePoint, said they will reduce their workforce by approximately 50 percent.
Fractyl Health is shifting its efforts toward weight‑loss maintenance following GLP‑1 therapy, while EyePoint is concentrating on developing treatments for vision loss associated with diabetes.